Relmada Therapeutics, Inc. (RLMD)
2.615
-0.50
(-15.92%)
USD |
NASDAQ |
Nov 20, 15:59
Relmada Therapeutics Enterprise Value : 129.70M for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | 129.70M |
| November 18, 2026 | 102.49M |
| November 17, 2026 | 119.03M |
| November 16, 2026 | 183.04M |
| November 13, 2026 | 247.06M |
| November 12, 2026 | 241.73M |
| November 11, 2026 | 270.53M |
| November 10, 2026 | 253.46M |
| November 09, 2026 | 239.59M |
| November 06, 2026 | 213.99M |
| November 05, 2026 | 200.12M |
| November 04, 2026 | 242.79M |
| November 03, 2026 | 253.46M |
| November 02, 2026 | 207.58M |
| October 30, 2026 | 179.84M |
| October 29, 2026 | 164.91M |
| October 28, 2026 | 155.30M |
| October 27, 2026 | 140.37M |
| October 26, 2026 | 142.50M |
| October 23, 2026 | 146.77M |
| October 22, 2026 | 148.90M |
| October 21, 2026 | 140.37M |
| October 20, 2026 | 156.37M |
| October 19, 2026 | 135.03M |
| October 16, 2026 | 128.63M |
| Date | Value |
|---|---|
| October 15, 2026 | 139.30M |
| October 14, 2026 | 143.57M |
| October 13, 2026 | 156.37M |
| October 12, 2026 | 172.38M |
| October 09, 2026 | 159.57M |
| October 08, 2026 | 136.10M |
| October 07, 2026 | 144.63M |
| October 06, 2026 | 147.84M |
| October 05, 2026 | 169.17M |
| October 02, 2026 | 181.98M |
| October 01, 2026 | 188.38M |
| September 30, 2026 | 200.12M |
| September 29, 2026 | 180.15M |
| September 28, 2026 | 186.55M |
| September 25, 2026 | 190.81M |
| September 24, 2026 | 188.68M |
| September 23, 2026 | 185.48M |
| September 22, 2026 | 234.55M |
| September 21, 2026 | 226.02M |
| September 18, 2026 | 221.75M |
| September 17, 2026 | 230.28M |
| September 16, 2026 | 232.42M |
| September 15, 2026 | 255.88M |
| September 14, 2026 | 255.88M |
| September 11, 2026 | 264.42M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Talphera, Inc. | 30.73M |
| Journey Medical Corp. | 103.50M |
| ANI Pharmaceuticals, Inc. | 1.754B |
| Corcept Therapeutics, Inc. | 6.745B |
| Veru, Inc. | 12.87M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.86M |
| Total Expenses (Quarterly) | 13.86M |
| EPS Diluted (Quarterly) | -0.1233 |
| Earnings Yield | -28.65% |
| Normalized Earnings Yield | -27.90 |